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MaOBJECTIVES This study sought to estimate the 2-year life expectancy (2YLE) (estimated survival rate >50% at 2 years)
in patients with critical limb ischemia (CLI) using the risk score based on predictors of all-cause mortality within 2 years.
BACKGROUND It has been reported that 2YLE is one of the important factors in the decision making of the
revascularization strategy. However, little is known about the probability and the prognostic factors of a 2YLE.
METHOD This study was performed as a multicenter retrospective analysis. Between March 2004 and December 2011,
995 CLI patients with follow-up period >730 days undergoing endovascular therapy (EVT) were identiﬁed and analyzed.
RESULTS Within 2 years, 412 patients (41%) died, and a cardiovascular cause accounted for 47% of deaths. On
multivariate analysis, the independent prognostic factors were age 65 to 79 years (odds ratio [OR]: 1.9), 80 years of age
or older (OR: 3.7), body mass index (BMI) 18.0 to 19.9 kg/m2 (OR: 1.5), BMI <18.0 kg/m2 (OR: 2.9), nonambulatory status
(OR: 2.4), hemodialysis (OR: 2.1), cerebrovascular disease (OR: 1.6), left ventricular ejection fraction (LVEF) of 40% to
49% (OR: 1.8), LVEF <40% (OR: 2.6), Rutherford class 5 (OR: 1.9), and Rutherford class 6 (OR: 3.4). The 2-year survival
rate in each risk score was calculated based on each OR (full score: 15 points). After that, 2YLE was estimated based on
the survival rate in each risk score, the probability of a 2YLE of$8 points indicated a <50% probability of 2-year survival.
CONCLUSIONS The independent prognostic factors for the 2YLE were age, BMI, nonambulatory status, hemodialysis,
cerebrovascular disease, LVEF, and tissue loss. A 2YLE score of $8 points indicated a <50% probability of 2-year
survival. This score seemed to be helpful for identifying CLI patients with a poor prognosis. (J Am Coll Cardiol Intv
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1445(4) were revised to indicate that life expectancy of $2
years is an important factor in the selection of the
initial revascularization procedure for CLI patients.SEE PAGE 1450
2YLE = 2-year life expectancy
BMI = body mass index
CI = conﬁdence interval
CLI = critical limb ischemia
EVT = endovascular therapy
LVEF = Left ventricular
ejection fraction
odds ratioThis approach is limited because CLI is a disease
with a poor prognosis, and it is difﬁcult to predict life
expectancy of $2 years before the revascularization
procedure. There are no deﬁnitive guidelines to
determine life expectancy in CLI patients, and this is
judged subjectively in actual clinical settings. There-
fore, the aim of this study was to identify prognostic
factors of 2-year mortality in CLI patients and to es-
timate the 2YLE on the basis of the risk score calcu-
lated by these prognostic factors.
METHODS
DATA COLLECTION. This study was performed as a
multicenter retrospective analysis of a prospectively
maintained database enrolling at 17 Japanese cardio-
vascular centers. The registration was performed in
accordance with the pre-speciﬁed criteria, and the
analysis was performed by an independent analyst.
The revascularization strategy was decided by each
institution in consultation with the department of
vascular or cardiovascular surgery. Between March
2004 and December 2011, 3,741 consecutive patients
underwent primary EVT for chronic infrainguinal
ischemia. With the exception of 1,868 claudicant pa-
tients, 497 patients with follow-up <730 days, and
381 patients with a lack of data, 995 patients were
included in this analysis.
PROCEDURES AND FOLLOW-UP. All patients re-
ceived dual-antiplatelet therapy (aspirin 100 mg/day
þ clopidogrel 75 mg/day) before the procedure. After
insertion of a 4- or 6-F sheath, an intra-arterial bolus
of 3,000 to 5,000 IU of heparin was injected, with
additional heparin given intravenously during the
procedure to maintain the activated clotting time at
>200 s. For superﬁcial femoral artery lesions, balloon
angioplasty was performed with a reference vessel
size. If a suboptimal result caused by ﬂow-limiting
dissection or residual stenosis of >30% was found
for a femoropopliteal lesion, a stent was implanted.
The lesion was basically covered by 2 types of bare
metal nitinol stents: Luminexx (Bard, Murray Hill,
New Jersey), and S.M.A.R.T. (Cordis J&J, Miami,
Florida). The stent size was chosen to be 1 to 2 mm
larger than the reference vessel diameter. For infra-
popliteal lesions, after passage of the guidewire, the
balloon angioplasty (not the drug-coated balloon),
and the vessel was expanded for at least 60 s. When
ﬂow-limiting dissection, signiﬁcant recoil or acuteocclusion was found after balloon angio-
plasty, balloon angioplasty was repeatedly
performed with low pressure, and a long
inﬂation time. Bailout stenting for infrapo-
pliteal lesion was not performed.
After the procedure, all patients were pre-
scribed lifelong aspirin (100 mg/day) and
prolonged (at least 1 month) clopidogrel 75
mg/day, ticlopidine 100 mg twice a day, or
cilostazol 100 mg twice a day was recom-
mended. Clinical information was obtained
within 30 days and at least every 6 months thereafter.
Cause of death was considered as cardiac in origin
unless obvious noncardiac causes could be identiﬁed.
Vascular death was deﬁned as that related to cerebral,
aortic, or peripheral vascular disease or renal disease.
Myocardial infarction was deﬁned as the detection of
an increase in cardiac troponin and/or creatine phos-
phokinase and with at least 1 of the following: 1)
symptoms of ischemia; 2) new or presumed new sig-
niﬁcant ST-segment T-wave changes; 3) development
of pathological Q waves on the electrocardiogram; 4)
imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality. Dyslipidemia
was regarded as low-density lipoprotein cholesterol
$140, triglyceride level $150, and high-density lipo-
protein cholesterol <40 or a patient under medical
treatment for dyslipidemia. Ambulatory status was
deﬁned as ambulatory (including crutch walking)
without a walking aid in daily life before the onset of
CLI. Patients requiring a walker or wheelchair or
bedridden patients were classiﬁed as nonambulatory.
A 2YLE was regarded as >50% probability of a 2-year
survival rate. Coronary artery disease was deﬁned as
stable angina with documented coronary artery dis-
ease, a history of percutaneous coronary intervention
or coronary artery bypass graft surgery, or previous
myocardial infarction. Cerebrovascular disease was
deﬁned as a hospital or neurologist report of the diag-
nosis of transient ischemic attack or ischemic stroke.
OUTCOME MEASURES. The primary outcome mea-
sure was to estimate the 2YLE by using the risk score
based on predictors of all-cause mortality within 2
years. The secondary outcome measures were causes
of death and prognostic factors at 2 years.
STATISTICAL ANALYSIS. Values are reported as mean
 SD. Continuous variables were examined using an
unpaired Student t test. Categorical variables were
compared by using the chi-square test. Logistic re-
gression analyses were performed to investigate the
association of baseline characteristics with the out-
come; the depend using variable was death within
2 years and the explanatory variables were the baseline
characteristics. The independent prognostic factors
OR =
TABLE 1 Patient Characteristics
Overall
(n ¼ 995)
Nonsurvivors
(n ¼ 412)
Survivors
(n ¼ 583) p Value
Age, yrs
<65 220 (22) 66 (70) 154 (30) <0.001
65–79 527 (53) 221 (58) 306 (42)
$80 248 (25) 125 (50) 123 (50)
Female 335 (34) 140 (34) 195 (33) 0.86
BMI, kg/m2
$20.0 647 (65) 221 (34) 426 (66) <0.001
18.0–19.9 213 (21) 106 (50) 107 (50)
<18.0 135 (14) 85 (63) 50 (37)
Ambulatory 560 (56) 156 (38) 404 (69) <0.001
Hypertension 745 (75) 304 (74) 441 (76) 0.51
Dyslipidemia 380 (38) 129 (31) 251 (43) <0.001
Diabetes 695 (70) 279 (68) 416 (71) 0.22
Hemodialysis 587 (59) 282 (68) 305 (52) <0.001
Current smoker 300 (30) 116 (28) 184 (32) 0.25
Cerebrovascular disease 272 (27) 140 (34) 132 (23) <0.001
Coronary artery disease 541 (54) 230 (56) 311 (53) 0.44
LVEF, %
$50 739 (74) 263 (36) 476 (64) <0.001
40–49 134 (13) 73 (54) 61 (46)
<40 120 (12) 75 (63) 45 (38)
Rutherford class
4 245 (25) 58 (14) 187 (32) <0.001
5 505 (51) 211 (51) 294 (50)
6 245 (25) 143 (35) 102 (17)
Tissue loss 750 (75) 354 (86) 396 (68) <0.001
Medication
Aspirin 784 (79) 334 (81) 450 (77) 0.14
Thienopyridine 385 (39) 151 (37) 234 (40) 0.27
Cilostazol 498 (50) 196 (48) 302 (52) 0.19
Statin 224 (23) 74 (18) 150 (26) 0.004
Beta-blocker 169 (20) 81 (22) 88 (18) 0.12
Anticoagulant agent 197 (20) 91 (22) 106 (18) 0.13
Values are n (%).
BMI ¼ body mass index; LVEF ¼ left ventricular ejection fraction.
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all the baseline characteristics were entered. The pre-
dictive risk score for assessing the 2YLE was thereafter
developed on the basis of another multivariate model
the explanatory variables of which were limited to all
the independent prognostic factors. In the develop-
ment of the risk score, weighted points on the basis of
the regression coefﬁcients in this model were assigned
to the prognostic factors. To develop such a simple
score that could be easily calculated in clinical practice,
the point of each prognostic factor was set between 1.0
and 3.0 points in 0.5-point units. The survival rates
observed in the study population were plotted ac-
cording to the developed risk scores. Error bars indicate
their 95% conﬁdence intervals (CIs) calculated by the
Clopper-Pearson exact method. The 2YLE was esti-
mated by the penalized cubic regression spline model.A p value <0.05 was considered to be signiﬁcant,
and 95% CIs were given when required. All statisti-
cal analyses were performed using SPSS Statistics
Version 19 (SPSS Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS. Of the 995 subjects
enrolled in the study, 412 (41%) died within 2 years.
The subjects in the nonsurvivor group were older
than those in the 2-year survivor group (74  10 vs. 71
 11 years of age, p < 0.0001). The rates of ambulatory
status (38% vs. 69%, p < 0.001), hyperlipidemia (31%
vs. 43%, p < 0.001), and use of a statin (38% vs 69%,
p < 0.001) were lower in the nonsurvivor group, and
those of hemodialysis (68% vs. 52%, p < 0.001), ce-
rebrovascular disease (34% vs. 23%, p < 0.001), and
Rutherford class (p < 0.001) were higher (Table 1).
CAUSES OF DEATH. The causes of death in the 412
subjects were cardiac in 121 (29%), vascular in 41
(10%), sudden death in 32 (8%), noncardiovascular in
191 (46%), and unknown in 27 (7%) (Table 2). Cardio-
vascular death, including sudden death, accounted
for 47% (194 of 412) of all deaths. The most common
cause of cardiac death in the nonsurvivor group was
heart failure, followed by acute myocardial infarction
and ventricular ﬁbrillation, which suggests that
management of heart failure and prevention of
ischemic cardiac events are important in CLI patients.
The noncardiovascular causes of death included
sepsis, pneumonia, and malignant tumors. A total of
142 subjects (34%) died of infectious disease, which
accounted for most of the noncardiovascular deaths.
2-YEAR LIFE EXPECTANCY. On multivariate analysis
of 2-year mortality (Figure 1), the independent prog-
nostic factors were 65 to 79 years of age (odds ratio
[OR]: 1.9; p < 0.001), 80 years of age or older (OR: 3.7;
p < 0.001), body mass index (BMI) 18.0 to 19.9 kg/m2
(OR: 1.5; p ¼ 0.022), BMI <18.0 kg/m2 (OR: 2.9; p <
0.001); nonambulatory status (OR: 2.4; p < 0.001),
hemodialysis (OR: 2.1; p < 0.001), cerebrovascular
disease (OR: 1.6; p ¼ 0.004), left ventricular ejection
fraction (LVEF) 40% to 49% (OR: 1.8; p ¼ 0.005),
LVEF <40% (OR: 2.6; p ¼ 0.005), Rutherford class 5
(OR: 1.9; p¼0.001), andRutherford class 6 (OR: 3.4; p<
0.001) (Table 3). Clinical procedural failure did not
affect the 2YLE (OR: 1.07; 95%CI: 0.60 to 1.91; p¼0.83).
Furthermore, bypass conversion after EVT did not
affect the 2YLE (OR: 1.14; 95%CI: 0.68 to 1.92; p¼0.62).
On the basis of the multivariate model, the risk
score for a 2YLE was developed (2YLE score, full
score: 15 points) (Table 4). Figure 1 shows the survival
rate when the subjects were stratiﬁed on the basis of
the scores speciﬁed for this study and the 2-year
TABLE 2 Causes of Death
Cardiac death (n ¼ 121, 29%)
Heart failure 45
Acute myocardial infarction 27
Ventricular ﬁbrillation 12
Aortic stenosis 5
Cardiogenic shock 4
Infectious endocarditis 1
Unknown 27
Vascular death (n ¼ 41, 10%)
Stroke 21
Renal failure 13
Ischemic colitis 7
Sudden death (n ¼ 32, 8%) 32
Noncardiovascular death (n ¼ 191, 46%)
Sepsis 72
Pneumonia 48
Other infection 22
Malignancy 21
Multiple organ failure 12
Intestinal bleeding 6
Unknown (n ¼ 27, 7% ) 27
Values are n.
FIGURE 1 Two-Year Life Expectancy in Each Risk Score
The plotted orange diamonds represent the 2-year life expectancy observed in the study
population when they were stratiﬁed according to the developed risk scores. Error bars
indicate their 95% conﬁdence intervals calculated by the Clopper-Pearson exact method.
The size of each diamond represents the sample number, which ranged from 1 (risk score¼
1, 14, and 14.5) to 102 (risk score ¼ 5). The bold green line represents the 2-year life
expectancy estimated by the penalized cubic regression spline model. The thin lines
indicate the 95% conﬁdence intervals.
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1447survival rate, which was estimated on the basis of the
scores speciﬁed for this study. Patients with a high
score had a higher risk of mortality. This scale pre-
dicts that patients with a score $8 points will not
likely survive for $2 years. Such patients accounted
for 31% (312 of 995) in the current study.
DISCUSSION
This study on the 2YLE of CLI patients undergoing
EVT revealed multiple mortality-related factors. This
ﬁnding suggests that a comprehensive assessment of
mortality risk, rather than assessment of a single
factor, will provide a more accurate predicted life
expectancy. Previous studies investigated prognostic
factors of perioperative death and composite out-
comes including mortality in CLI patients undergoing
EVT. They reported that the prognostic factors
include gangrene, renal failure, heart failure,
BMI <18, nonambulatory status, and left ventricular
dysfunction (5,6). These ﬁndings suggest that EVT
seems to be appropriate as ﬁrst-line therapy in CLI
patients with a shorter life expectancy. Although the
importance of this concept has been fully understood,
it is actually difﬁcult to carry out in daily practice.
From these standpoints, it was considered that there
are quite a few meanings of this study.
Cardiovascular death is the most common cause of
death in patients with peripheral arterial disease (7),
but causes of death in CLI patients have not been
fully studied. Cardiac death and infectious diseaseswere the main causes of death in the current study.
Infectious disease, including sepsis and pneumonia,
occurred in 142 subjects (34%) and was the most
common noncardiovascular cause of death.
With regard to oral medication, the efﬁcacy of sta-
tins (8) and optimal medical therapy (9) for the pre-
vention of cardiovascular events has been reported in
clinical guidelines (7). In the current study, the uni-
variate analysis showed that life expectancy was
associated with oral administration of aspirin (OR: 1.5;
p ¼ 0.04), thienopyridine (OR: 0.9; p ¼ 0.35), cil-
ostazol (OR: 0.7; p ¼ 0.047), anticoagulant agent (OR:
1.1; p ¼ 0.65), statin (OR: 0.8; p ¼ 0.39), and beta-
blocker (OR: 1.4; p ¼ 0.11), but none of these oral
drugs emerged as independent predictors on multi-
variate analysis. The variable stepwise selection
model also did not identify any of these drugs as
important factors. One possible explanation might be
that a longer observation period is needed for these
therapies to provide beneﬁcial effects on the preven-
tion of cardiovascular events. Another explanation
might be that the common causes of 2-year mortality
were infectious diseases and sudden death, in addi-
tion to cardiovascular events; the impact of cardio-
vascular events on all-cause mortality might be
relatively small in CLI patients. However, the inﬂu-
ence of medical therapy on CLI remains unclear. To
verify these ﬁndings, detailed data regarding medical
therapy including follow-up are needed.
The 2YLE is an important factor in the selection
of bypass surgery or EVT in CLI patients (2), but
TABLE 3 Predictors of Death
Univariate Model
Unadjusted OR (95% CI)
Multivariate Model 1
Adjusted OR (95% CI)
Multivariate Model 2
Adjusted OR (95% CI)
Male 1.0 (0.7–1.3), p ¼ 0.861 0.8 (0.6–1.2) (p ¼ 0.314)
Age, yrs
<65 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
65–79 1.7 (1.2–2.4), p ¼ 0.002 2.0 (1.3–2.9), p < 0.001 1.9 (1.3–2.8), p < 0.001
$80 2.4 (1.6–3.5), p < 0.001 3.6 (2.2–5.7), p < 0.001 3.7 (2.3–5.8), p < 0.001
Body mass index (vs. $20.0 kg/m2) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
18.0–19.9 1.9 (1.4–2.6), p < 0.001 1.5 (1.0–2.1), p ¼ 0.039 1.5 (1.1–2.2), p ¼ 0.022
<18.0 3.3 (2.2–4.8), p < 0.001 2.8 (1.8–4.3), p < 0.001 2.9 (1.9–4.5), p < 0.001
Nonambulatory status 3.7 (2.8–4.8), p < 0.001 2.4 (1.8–3.3), p < 0.001 2.4 (1.7–3.2), p < 0.001
Hypertension 0.9 (0.7–1.2), p ¼ 0.506 1.1 (0.8–1.6), p ¼ 0.507
Hyperlipidemia 0.6 (0.5–0.8), p < 0.001 0.8 (0.6–1.1), p ¼ 0.118
Diabetes mellitus 0.8 (0.6–1.1), p ¼ 0.218 0.8 (0.6–1.2), p ¼ 0.315
Smoking 0.8 (0.6–1.1), p ¼ 0.249 1.2 (0.9–1.7), p ¼ 0.234
Hemodialysis 2.0 (1.5–2.6), p < 0.001 2.2 (1.6–3.0), p < 0.001 2.1 (1.6–2.9), p < 0.001
Cerebrovascular disease 1.8 (1.3–2.3), p < 0.001 1.6 (1.2–2.2), p ¼ 0.004 1.6 (1.2–2.2), p ¼ 0.004
Coronary artery disease 1.1 (0.9–1.4), p ¼ 0.439 0.9 (0.7–1.3), p ¼ 0.728
Ejection fraction, % (vs. $50%) 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
40–49 2.2 (1.5–3.1), p < 0.001 1.8 (1.2–2.8), p ¼ 0.006 1.8 (1.2–2.8), p ¼ 0.005
<40 3.0 (2.0–4.5), p < 0.001 2.7 (1.7–4.2), p < 0.001 2.6 (1.7–4.0), p < 0.001
Rutherford classiﬁcation (vs. class 4) 0.0 (0.0–0.0), p < 0.001 0.0 (0.0–0.0), p < 0.001 0.0 (0.0–0.0), p < 0.001
Class 5 2.3 (1.6–3.3), p < 0.001 1.9 (1.3–2.8), p < 0.001 1.9 (1.3–2.7), p ¼ 0.001
Class 6 4.5 (3.1–6.7), p < 0.001 3.4 (2.2–5.4), p < 0.001 3.4 (2.2–5.2), p < 0.001
Isolated infrapopliteal disease 1.0 (0.8–1.3), p ¼ 0.900 1.0 (0.7–1.4), p ¼ 0.953
In multivariate model 1, all the baseline characteristics were entered. In the multivariate model 2, the variables that were signiﬁcant in the multivariate model 1 were entered.
CI ¼ conﬁdence interval; OR ¼ odds ratio; Ref. ¼ reference.
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1448this decision is not easy. In this study, we scored
the predictors of the 2YLE, and stratiﬁed the risk
to evaluate the 2YLE. Several studies predicted
the prognosis using a single factor (10), prognostic
factors (11,12), and scoring systems (13,14), but this
is the ﬁrst study to evaluate the 2YLE on the basis ofTABLE 4 Two-Year Life Expectancy Score in CLI Patients
Variables Score*
Nonambulatory status 2.0
Rutherford class
5 1.5
6 3.0
Cerebrovascular disease 1.0
Hemodialysis 2.0
BMI, kg/m2
18.0–19.9 1.0
<18.0 2.0
Age, yrs
65–79 1.5
$80 3.0
Ejection fraction, %
40–49 1.5
<40 2.0
*Full score ¼ 15 points.
BMI ¼ body mass index; CLI ¼ critical limb ischemia.multiple independent prognostic factors for 2-year
mortality, including age, BMI, nonambulatory status,
hemodialysis, cerebrovascular disease, LVEF, and
tissue loss. Our results suggest that a scoring system
on the basis of a combination of these factors can help
to predict life expectancy and may make an important
contribution to deciding on a treatment strategy for
CLI patients. Patients with scores $8 points have
a 2YLE <50%, which suggests that EVT is preferable
for revascularization in these cases. Furthermore,
because a graft of a diameter #3 mm is likely to be
occluded (15) and severe ischemic heart disease and
heart failure are at high risk with general anesthesia,
EVT will be also favorable for patients without a good
vein conduit and with these severe comorbidities,
even if the patients had a score of <8 points ($50%
probability of 2-year survival). However, this study
was performed with only patients undergoing EVT,
not all CLI patients, because those who underwent
bypass surgery were not included. Because the aim of
this study was to aid the decision-making process
about different procedures (EVT or bypass), it seemed
to be a weak point that it does not include patients
who underwent a bypass. However, in this study, it
is difﬁcult to compensate for the selection bias.
Therefore, future work should include prospectively
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 2 , 2 0 1 4 Soga et al.
D E C E M B E R 2 0 1 4 : 1 4 4 4 – 9 2-Year Life Expectancy in CLI Patients
1449assessing the ability of the score to predict life
expectancy before the score is used clinically.
STUDY LIMITATIONS. First, the study was a retro-
spective analysis, despite the use of a large-scale
prospectively maintained database. Second, selec-
tion bias could be present because the evaluation of
2YLE in CLI patients excluded 128 patients with
missing data and 497 patients who were not known to
be dead or alive and had a follow-up period <730
days. Exclusion of these patients could have caused
the mortality to be overestimated. The validation in a
separate sample should be performed. Also, this
analysis does not include CLI patients who under-
went bypass surgery. Therefore, the possibility of
selection bias cannot be denied. Further investigation
is needed to judge the validity of these ﬁndings in
both treatments (EVT and bypass surgery), although
it has been reported that the mortality up to 2 years
between CLI patients who underwent revasculariza-
tion was almost similar (1). Last, multiple factors that
are considered to be historically important may in-
ﬂuence the evaluation of the 2YLE, but this study
focused on database items only. Therefore, other
factors such as socioeconomic status and insurance
status, which were not evaluated in this study, maybe prognostic factors. Overall health status such as
frailty (16,17) should be included in the prediction of
life expectancy of CLI patients. Collection of more
data is needed to examine the effects of frailty and
other factors on life expectancy in these patients.
CONCLUSIONS
We evaluated the causes of death and the 2YLE in CLI
patients. The most common causes of death were
cardiovascular events and infections, and the inde-
pendent prognostic factors for the 2YLE were age,
BMI, ambulatory status, hemodialysis, cerebrovascu-
lar disease, LVEF, and tissue loss. A 2YLE score was
calculated from the hazard ratios for these factors. A
score of $8 points indicated a <50% probability of 2-
year survival. We suggested that this score seemed to
be helpful for identifying CLI patients with a poor
prognosis who may be more suitably treated with EVT
rather than bypass surgery.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Yoshimitsu Soga, Department of Cardiology, Kokura Me-
morial Hospital, 1-2-3 Asano, Kokurakita-ku, Kitakyushu
8020001, Japan. E-mail: sogacchy@yahoo.co.jp.RE F E RENCE S1. Adam DJ, Beard JD, Cleveland T, et al. Bypass
versus angioplasty in severe ischaemia of the leg
(BASIL): multicentre, randomised controlled trial.
Lancet 2005;366:1925–34.
2. Bradbury AW, Adam DJ, Bell J, et al. Bypass
versus Angioplasty in Severe Ischaemia of the Leg
(BASIL) trial: an intention-to-treat analysis of
amputation-free and overall survival in patients
randomized to a bypass surgery-ﬁrst or a balloon
angioplasty-ﬁrst revascularization strategy. J Vasc
Surg 2010;51:5S–17S.
3. Tendera M, Aboyans V, Bartelink ML, et al. ESC
Guidelines on the diagnosis and treatment of pe-
ripheral artery diseases: Document covering
atherosclerotic disease of extracranial carotid and
vertebral, mesenteric, renal, upper and lower ex-
tremity arteries: the Task Force on the Diagnosis
and Treatment of Peripheral Artery Diseases of the
European Society of Cardiology (ESC). Eur Heart J
2011;32:2851–906.
4. Rooke TW, Hirsch AT, Misra S, et al. 2011
ACCF/AHA focused update of the guideline for
the management of patients with peripheral
artery disease (updating the 2005 guideline):
a report of the American College of Cardiology
Foundation/American Heart Association Task
Force on Practice Guidelines: developed in
collaboration with the Society for Cardiovascular
Angiography and Interventions, Society of Inter-
ventional Radiology, Society for Vascular Medi-
cine, and Society for Vascular Surgery. J Am Coll
Cardiol 2011;58:2020–45.5. Vogel TR, Dombrovskiy VY, Carson JL, et al. In-
hospital and 30-day outcomes after tibioperoneal
interventions in the US Medicare population with
critical limb ischemia. J Vasc Surg 2011;54:109–15.
6. Iida O, Soga Y, Hirano K, et al. Midterm out-
comes and risk stratiﬁcation after endovascular
therapy for patients with critical limb ischaemia
due to isolated below-the-knee lesions. Eur J Vasc
Endovasc Surg 2012;43:313–21.
7. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-
Society Consensus for the Management of Pe-
ripheral Arterial Disease (TASC II). J Vasc Surg
2007;45 Suppl S:S5–67.
8. Westin GG, Armstrong EJ, Bang H, et al. Asso-
ciation between statin medications and mortality,
major adverse cardiovascular event, and
amputation-free survival rates in patients with
critical limb ischemia. J Am Coll Cardiol 2013;
S0735-1097(13)06209-8.
9. Chung J, Timaran DA, Modrall JG, et al. Optimal
medical therapy predicts amputation-free survival
in chronic critical limb ischemia. J Vasc Surg 2013;
58:972–80.
10. Domenick N, Saqib NU, Marone LK, et al.
Impact of gender and age on outcomes of
tibial artery endovascular interventions in
critical limb ischemia. Ann Vasc Surg 2012;26:
937–45.
11. Conte MS, Bandyk DF, Clowes AW, et al. Re-
sults of PREVENT III: a multicenter, randomized
trial of edifoligide for the prevention of vein graftfailure in lower extremity bypass surgery. J Vasc
Surg 2006;43:742–51.
12. Meltzer AJ, Evangelisti G, Graham AR, et al.
Determinants of outcome after endovascular
therapy for critical limb ischemia with tissue loss.
Ann Vasc Surg 2014;28:144–51.
13. Moxey PW, Brownrigg J, Kumar SS, et al. The
BASIL survival prediction model in patients with
peripheral arterial disease undergoing revascular-
ization in a university hospital setting and com-
parison with the FINNVASC and modiﬁed
PREVENT scores. J Vasc Surg 2013;57:1–7.
14. Arvela E, Söderström M, Korhonen M, et al.
Finnvasc score and modiﬁed Prevent III score pre-
dict long-term outcome after infrainguinal surgical
and endovascular revascularization for critical limb
ischemia. J Vasc Surg 2010;52:1218–25.
15. Slim H, Tiwari A, Ritter JC, et al. Outcome of
infra-inguinal bypass grafts using vein conduit
with less than 3 millimeters diameter in critical leg
ischemia. J Vasc Surg 2011;53:421–5.
16. Fried LP, Tangen CM, Walston J, et al. Frailty in
older adults: evidence for a phenotype. J Gerontol
A Biol Sci Med Sci 2001;56:M146–56.
17. Fried LP, Ferrucci L, Darer J, et al. Untangling
the concepts of disability, frailty, and comorbidity:
implications for improved targeting and care.
J Gerontol A Biol Sci Med Sci 2004;59:255–63.
KEY WORDS critical limb ischemia,
endovascular therapy, life expectancy
